Ongoing Clinical Trials for Brain Cancer Metastatic
Currently, there is 1 ongoing clinical trial for patients with brain cancer metastatic. This trial is investigating a new imaging agent that may help doctors better visualize cancer that has spread to the brain, particularly in relation to HER2 protein expression.
Clinical trial locations
Study on 68Ga-NOTA-Anti-HER2 VHH1 for Cancer Patients with Brain Metastasis
This clinical trial is investigating a specialized imaging agent called 68Ga-NOTA-Anti-HER2 VHH1 in patients whose cancer has spread to the brain. The study aims to understand how well this agent can target and help visualize brain metastases, particularly comparing its effectiveness between patients with HER2-positive and HER2-negative cancers.
Who can participate:
- Adults aged 18 years or older
- Patients with cancer that has spread to the brain (brain metastasis)
- At least one brain lesion measuring 8 mm or larger on CT or MRI scans
- Cancer that is potentially HER2-positive, meaning previous HER2 testing has been done or sufficient tissue is available for testing
- Ability to provide informed consent
Who cannot participate:
- Patients without brain metastases
- Patients outside the specified age range
- Patients whose HER2 status cannot be determined
- Patients who belong to vulnerable populations requiring special protection
What the trial involves:
The main focus of this study is to compare how the imaging agent 68Ga-NOTA-Anti-HER2 VHH1 is taken up by brain metastases in patients with different HER2 statuses. HER2 is a protein found on some cancer cells that can influence cancer growth and behavior. The imaging agent is designed to bind to this protein, making the cancer cells more visible on scans.
Participants will receive the imaging agent through an intravenous injection. A nuclear medicine physician will then examine the images to assess whether the treatment successfully targets the brain metastases. This evaluation is done without the physician knowing the patient’s HER2 status to ensure unbiased results. The uptake is measured using Standard Uptake Values (SUV), which quantifies how much of the agent is absorbed by the cancer cells.
If available, the study will also track how uptake changes during and after any other treatments the patient may be receiving, comparing these findings to the patient’s overall disease progression. This trial, which began recruiting in October 2017, is expected to conclude by December 31, 2026.
Investigational drug:
The agent being studied is 68Ga-NOTA-Anti-HER2 VHH1, a radiopharmaceutical used for diagnostic imaging. It works by binding to the HER2 protein, which is often overexpressed on certain cancer cells. This binding allows doctors to better visualize where cancer has spread in the brain, helping them understand the extent and behavior of the metastases.
Summary
There is currently one ongoing clinical trial for patients with brain cancer metastatic, taking place in Belgium. This trial focuses on advancing diagnostic imaging techniques rather than testing a traditional treatment drug. The study specifically investigates whether the imaging agent 68Ga-NOTA-Anti-HER2 VHH1 can effectively identify brain metastases based on HER2 protein expression, which could potentially help doctors make more informed treatment decisions in the future. Patients interested in participating should have confirmed brain metastases and meet the specific age and tissue availability requirements outlined in the trial.